Introduction {#S1}
============

The dominantly inherited spinocerebellar ataxias (SCAs) represent a large and heterogeneous group of neurodegenerative diseases mainly characterized by progressive loss of balance and coordination often associated with slurred speech ([@B107]). SCA symptoms mainly arise from the progressive degeneration of the cerebellum, brainstem and associated structures. In the cerebellum, Purkinje cells are the neuronal population the most frequently affected. Other central and peripheral nervous structures can be affected and contribute to additional and diverse symptoms. The estimated prevalence of SCAs is 1--5 per 100,000 individuals, but varies markedly depending on geography and ethnicity ([@B166]).

Among this group, SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17 share a common causative mutation that is the expansion of a CAG repeat sequence located within the coding region of specific genes, which translates into a polyglutamine (polyQ) tract in the corresponding proteins: Ataxin-1 (ATXN1), ATXN2, ATXN3, the α1A subunit of the Cav2.1 voltage-gated calcium channel (CACNA1A), ATXN7, and the TATA-box-binding protein (TBP), respectively. Other polyQ disorders include Huntington's disease (HD), the spinobulbar muscular atrophy and the dentatorubral-pallidoluysian atrophy. The normal polyQ tract in SCA proteins is generally polymorphic in length, while beyond an apparent threshold the diseases become fully penetrant. Depending on the SCA, the pathogenic properties of the mutated protein can appear with an expansion ranging from 20 to several hundreds of glutamines ([@B16]). PolyQ SCAs are generally adult onset disorders and progress over 10--20 years before leading to death of patients ([@B107]). However, longer polyQ expansions are associated with earlier onset of symptoms and a broader range of neurological symptoms in juvenile forms.

Despite their similarities, the polyQ SCAs differ in many aspects. While SCA proteins bear a similar expandable polyQ tract, they do not share any other domain and have different cellular functions. Even if they are ubiquitously expressed, they cause relatively distinct pattern of neurodegeneration accounting for SCA specific clinical features. Therefore, the particularities of each polyQ SCA is believed to come from the protein context into which the polyQ expansion is embedded.

The exact pathogenic mechanisms underlying polyQ SCAs are not fully understood ([@B16]). Current studies indicate a complex mechanism involving the disruption of the native protein functions -through gain or loss of function- and the toxic gain of function conveyed by the polyQ expansion. A major and common impact of polyQ expansion on proteins is a conformational change leading to misfolding, progressive intracellular accumulation and the formation of large insoluble protein aggregates containing the mutant protein. While it is still under debate whether large polyQ aggregates play a role in SCA pathogenesis, the aggregation is known to proceed stepwise generating small soluble oligomeric species, which are thought to induce proteotoxicity ([@B16]).

PolyQ SCAs pathogenesis leads to progressive alterations of several cellular functions including autophagy, ubiquitin-proteasome degradation, calcium homeostasis, neurotransmission, and mitochondrial energy production, which contribute to neuronal dyshomeostasis and progressive death ([@B107]; [@B139]; [@B16]). Early studies also reported that changes in gene expression are central features in polyQ SCAs. Many groups have emphasized the interactions of polyQ SCA proteins with different factors and co-regulators of gene transcription, DNA sequences and proteins involved in RNA metabolism ([Table 1](#T1){ref-type="table"}). Moreover, misfolded SCA proteins progressively accumulate in neuronal nuclei where they form aggregates that sequester nuclear proteins or perturb the nuclear proteostasis network. It is noteworthy that preventing the nuclear localization of polyQ SCAs often mitigates disease features in experimental model systems. Finally, changes in gene expression are observed at disease onset in different animal models of polyQ SCAs, accounting for diverse cellular dysfunctions, but also likely reflect some compensatory responses to proteotoxicity ([Table 2](#T2){ref-type="table"}).

###### 

Cellular function and main interactors of polyQ SCA proteins.

  **Disease**   **Causative gene/protein**                  **Cellular function of disease associated protein**           **Main interactors**               **Cellular function**                         **References**
  ------------- ------------------------------------------- ------------------------------------------------------------- ---------------------------------- --------------------------------------------- -------------------------
  SCA1          *ATXN1*/ataxin-1 (ATXN1)                    Transcription; RNA metabolism                                 ATXN1L (BOAT)                      Transcription; corepressor                    [@B143]; [@B15]
                                                                                                                          CIC                                Transcriptional repressor                     [@B123]; [@B165]
                                                                                                                          HDAC3                              Histone deacetylation, epigenetic repressor   [@B205]
                                                                                                                          LANP                               Inhibitor of histone acetyltransferases       [@B131]; [@B42], [@B41]
                                                                                                                          PQBP-1                             Transcription; splicing                       [@B150]
                                                                                                                          RBM17                              Splicing                                      [@B123]
                                                                                                                          RORa/TIP60                         Transcriptional activation                    [@B184]
                                                                                                                          SMRT/NCOR2                         Transcriptional corepressor                   [@B201]
  SCA2          *ATXN2*/ataxin-2 (ATXN2)                    RNA metabolism; translation                                   PABP-1                             mRNA splicing and stability                   [@B173]
                                                                                                                          A2BP1/Fox1                         Splicing                                      [@B187]
                                                                                                                          DDX6                               RNA degradation                               [@B148]
                                                                                                                          TDP-43                             RNA processing; transcription                 [@B54]
  SCA3          *ATXN3*/ataxin-3 (ATXN3)                    Deubiquitinase; transcriptional regulator                     CBP/PCAF/P300                      Histone acetylation                           [@B24]; [@B121]
                                                                                                                          HDAC3/NCOR                         Histone deacetylation                         [@B60]; [@B61]
                                                                                                                          FOXO4                              Transcriptional activation                    [@B5]
                                                                                                                          TBP                                Basal transcription                           [@B5]
                                                                                                                          PML                                Nuclear bodies                                [@B24]
  SCA6          *CACNA1A*/α1A subunit of Cav2.1 and α1ACT   Calcium channel subunit and transcriptional activator         AT-rich and CA-rich DNA elements   Enhancers                                     [@B50]
  SCA7          *ATXN7*/ataxin-7 (ATXN7)                    SAGA component; co-activator of RNAPII-driven transcription   GCN5                               Histone acetylation                           [@B85]
                                                                                                                          USP22                              Histone deubiquitinase                        [@B85]
                                                                                                                          CRX                                Transcriptional activation                    [@B110]; [@B28]
                                                                                                                          RORa                               Transcriptional activation                    [@B193]
                                                                                                                          SIRT1                              Deacetylase                                   [@B192]
                                                                                                                          TBP                                Basal transcription                           [@B154]
  SCA17         *TBP*/TATA-box binding protein (TBP)        TFIID component; basal transcription                          DNA elements                       Promoter regions                              [@B64]
                                                                                                                          TFIIB                              General transcription                         [@B63]
                                                                                                                          XBP1                               Transcriptional activation                    [@B220]
                                                                                                                          MYOD                               Transcriptional activation                    [@B82]
                                                                                                                          SP1                                Transcriptional activation                    [@B185]

###### 

Gene expression impairments in polyQ SCA mouse models.

  **Disease**   **Mouse model name**   **Design**                                                  **Mutant protein expression**                                  **Phenotypes and neuropathology**                                                       **Deregulation of genes, pathways and epigenetic**                                                                                                             **References**
  ------------- ---------------------- ----------------------------------------------------------- -------------------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------
  SCA1          SCA1\[82Q\]            Tg; *Pcp-2* promoter, *ATXN1* cDNA with 82 CAGs             PC; overexpress                                                Motor phenotype; cerebellar and PC pathology                                            LTD; Glutamate signaling in PC; Cell signal transduction; calcium homeostasis; multicellular impairments: PCP; IO: immune system, ISG                          [@B124]; [@B183]; [@B95]; [@B49]
                Atxn1^154Q/2Q^         KI;154 CAGs in *Atxn1*                                      Ubiquitous; endogenous level                                   Motor phenotype; cerebellar and PC pathology                                            PC: cellular signaling pathways; *Igfbp5* and IGF pathway crosstalk PC-GC; medulla: metabolic pathways; IO: immune system; ISG; histone H3 hypoacetylation     [@B68]; [@B41]; [@B49]
  SCA2          SCA2-127Q              Tg; *Pcp-2* promoter, *ATXN2* cDNA with 127 CAGs            PC; overexpress                                                Motor phenotype; cerebellar and PC pathology                                            LTD; phosphatidylinositol; calcium homeostasis; small GTPase-mediated signaling; mRNA transport; synaptogenesis; axon guidance                                 [@B78]; [@B156]
                BAC-Q72                Tg; BAC containing human *ATXN2* with 72 CAGs               Brain; endogenous level; overexpress in PC and basal ganglia   Motor phenotype; cerebellar and PC pathology                                            Calcium homeostasis; Glutamate signaling; voltage-gated ion channel activity                                                                                   [@B43]
                Atxn2-CAG100           KI; 100 CAGs in *Atxn2*                                     Ubiquitous; endogenous level                                   Motor phenotype                                                                         Myelination                                                                                                                                                    [@B179]
  SCA3          Ataxin-3-Q79           Tg; Prion promoter, *ATXN3* cDNA with 79 CAGs;              Whole brain except PC; overexpress                             Motor phenotype; cerebellar and PC pathology                                            LTD; Glutamate signaling in PC; Cell signal transduction; calcium homeostasis; GABA receptors; gene expression regulators; histone H3 and H4 hypoacetylation   [@B35]
                YAC84Q (MJD84.2)       Tg; YAC containing *ATXN3* with 76--77 CAGs                 Ubiquitous; endogenous level                                   No motor phenotype                                                                      CREB signaling; cholesterol biosynthesis; myelination; striatum: axon guidance; neurotransmission brainstem: cell signaling; aa metabolism                     [@B198]
                SCA3                   KI; 82 CAGs in *Atxn3*                                      Ubiquitous; endogenous level                                   No motor phenotype                                                                      Myelination                                                                                                                                                    [@B160]
  SCA6          PCαACT~SCA6~           Tg; *Pcp-2* promoter, *α1ACT* cDNA with 33 CAGs             PC; overexpress                                                Weak motor phenotype; cerebellar and PC pathology                                       Neurite outgrowth; neuronal differentiation                                                                                                                    [@B50]
                SCA6-MPI^118Q/118Q^    KI; 118 CAGs in *Cacna1a*                                   Ubiquitous; endogenous level                                   Motor phenotype; cerebellar and PC pathology                                            GPCR signaling; Neuroinflammation                                                                                                                              [@B3]
  SCA7          R7E                    Tg; *Rho promoter*, *ATXN7* cDNA with 90 CAGs               Rod photoreceptors; overexpress                                Photoreceptor dysfunction and dystrophy                                                 Phototransduction pathway; H3 hypoacetylation                                                                                                                  [@B1]
                ataxin-7-Q52           Tg; PDGF-B promoter, *ATXN7* cDNA with 52 CAGs              Brain; overexpress                                             Motor phenotype; cerebellar and PC pathology                                            Myelination; synaptic transmission; signal transduction; axon transport; neuronal differentiation                                                              [@B32]
                PrP-SCA7-92Q           Tg; Prion promoter, *ATXN7* cDNA with 92 CAGs               Whole brain except PC; overexpress                             Photoreceptor dysfunction and dystrophy; Motor phenotype; cerebellar and PC pathology   Phototransduction pathway; H3 hypoacetylation                                                                                                                  [@B110]; [@B152]
                Gfa2-SCA7-92Q          Tg; *Gfa2* promoter, *ATXN7* cDNA with 92 CAGs              Bergmann glia                                                  Motor phenotype; cerebellar and PC pathology                                            Glutamate transporter genes                                                                                                                                    [@B40]
                mPrP-fx SCA7-92Q BAC   Tg; Prion promoter in BAC *ATXN7* cDNA with 92 CAGs; eGFP   Whole brain; endogenous level                                  Motor phenotype; cerebellum and PC pathology                                            Phosphatidylinositol and calcium signaling                                                                                                                     [@B192]
                SCA7^266Q/5Q^          KI; 266 CAGs in *Atxn7*                                     Ubiquitous; endogenous level                                   Photoreceptor dysfunction and dystrophy; motor phenotype; cerebellar and PC pathology   Phototransduction pathway; transcription factor; MHC class I; cell signaling; *Igfbp5* and IGF pathway                                                         [@B225]; [@B68]
  SCA17         TBP-71Q/TBP-105Q       Tg; Prion promoter, *TBP* cDNA with 71 or 105 CAGs          Whole brain except PC; overexpress                             Motor phenotype; cerebellar and PC pathology                                            Downregulation of *Hspb1* and *HSPA5*                                                                                                                          [@B63]; [@B91]
                TBP-105Q               KI; 105 CAGs in *Tbp*                                       Ubiquitous; endogenous level                                   Motor phenotype; cerebellar and PC pathology skeletal muscle phenotype                  Synaptic transmission; calcium signaling; immune system; muscle specific genes                                                                                 [@B220]; [@B92]; [@B127]

Tg, transgenic; KI, knockin; YAC, yeast artificial chromosome; BAC, bacterial artificial chromosome; PC, Purkinje cells; GC, granule cells; IO, inferior olive; GPCR, G-protein coupled receptor; PCP, planar cell polarity; ISG, interferon stimulated gene; aa, amino acid.

In this review, we summarize our current understanding of gene deregulation mechanisms and consequences in the pathogenesis of polyQ SCAs. We also highlight the still poorly investigated roles of epigenetic mechanisms and cell-type specific regulatory networks and we bring up some critical questions such as the role of transcription buffering, nuclear protein quality controls (nPQC) and aging to elucidate the disease-specific and common pathomechanisms of polyQ SCAs.

Deregulation of Gene Expression and Epigenetic {#S2}
==============================================

SCA1 {#S2.SS1}
----

SCA1 is caused by the expansion of CAG triplets to 39 or more repeats in the *ATXN1* gene, which translates into an expanded polyQ domain in ATXN1 ([@B151]). The disease progresses the most rapidly within polyQ SCA subtypes ([@B98]), causing a progressive gait ataxia, dysarthria, neuropathies, nystagmus and slurred speech ([@B231]; [@B107]). Although wild type ATXN1 is widely expressed, mutant ATXN1 (mATXN1) causes olivopontocerebellar atrophy with selective degeneration of Purkinje cells and neurons in the deep cerebellar nuclei, the brainstem and the spinal cord ([@B231]; [@B107]).

ATXN1 localizes to the nucleus and is mainly known for its repressor function in gene expression ([@B106]; [@B201]; [@B112]; [@B13]; [@B205]). ATXN1 interacts with multiple nuclear proteins involved in transcription regulation such as HDAC3, RORa/TIP60 complex, CIC, LANP, SMRT/NCOR2 complex, HDAC4/MEF2 complex, ATXN1L (BOAT), GFI-1, 14-3-3, Sp1, A1Up, PQBP1 ([@B131]; [@B45]; [@B150]; [@B27]; [@B201]; [@B143]; [@B202]; [@B112]; [@B184]; [@B13]; [@B71]; [@B123]), and also with the RNA-binding protein RBM17 ([@B227]; [@B30]; [@B123]). Some of these interactions are mediated by the HMG-box protein 1 (AXH) domain of ATXN1 and are modulated by the phosphorylation of its serine 776 (Ser776) ([@B227]; [@B30]; [@B201]; [@B143]; [@B202]; [@B112]; [@B184]; [@B123]; [@B69]). mATXN1 shows altered interactions with many of these natural partners, leading to gene deregulation and neuronal degeneration in SCA1 cellular and mouse models. In addition, mATXN1 accumulates and aggregates in neuronal nuclei of SCA1 patients' brain and model systems ([@B189]; [@B39]), and sequesters interactors, which accounts for their dysfunction. Importantly, gene deregulations precede behavioral impairments in mouse models ([@B124]; [@B183]) and mutation in mATXN1 nuclear localization signal abolishes the phenotypes, pointing out the nuclear origin of the toxicity ([@B106]).

Studies on gene deregulation in SCA1 are rich and cover multiple aspects. One of the first mechanism proposed to alter gene expression was through the dysfunction of PQBP1, a binding partner of RNA polymerase II (RNAPII) enriched in brain regions degenerating in SCA1. The expression of mATXN1 in cultured cells increases the binding of PQBP1 to RNAPII, diminishing the level of phosphorylated form of RNAPII, and hence reducing transcription ([@B150]). Consistently, the phosphorylation of RNAPII is decreased in the cerebellar cortex of SCA1\[82Q\] transgenic mice ([@B150]), suggesting that transcription elongation mediated by phospho-RNAPII may be impaired in the disease.

Several evidences indicate that mATXN1 affects the genetic program of Purkinje cells development and maintenance. Firstly, SCA1\[82Q\] transgenic mice expressing mATXN1 specifically in Purkinje cells show that behavioral phenotypes occur after the Purkinje cells pathology, which is characterized by the downregulation of Purkinje cells genes involved in glutamate signaling, long term depression (LTD) and calcium homeostasis (e.g., *Itpr1*, *Serca2*, *Eaat4*, *Trpc3*, and *Inpp5A*) ([@B124]; [@B183]). SCA1\[82Q\] transgenic mice in which mATXN1 conditional expression was induced after completion of cerebellar development, present milder phenotypes than mice expressing mATXN1 during post-natal cerebellar development ([@B232]; [@B184]). Secondly, the expression level of retinoid acid receptor-related orphan receptor alpha (RORa) is decreased in the cerebellum of SCA1\[82Q\] transgenic mice. RORa is crucial for the development and maintenance of Purkinje cells and *Rora* gene mutation in *Staggerer* mice leads to cerebellar defects and ataxia ([@B77]; [@B184]). SCA1\[82Q\] transgenic and *Staggerer* mice share common deregulated genes involved in calcium and glutamate signaling ([@B124]; [@B183]). A loss-of-function mutation for several of these genes such as *Calb1, Itpr1, Grm1* causes ataxia ([@B89]). Consistently, RORa haploinsufficiency in SCA1\[82Q\] transgenic mice worsens the pathology ([@B184]). Thirdly, ATXN1 interacts with the Tat Interacting Protein, 60 kDa (TIP60, also named KAT5), an histone acetyltransferase (HAT), to form a complex with RORa. PolyQ expansion in ATXN1 reinforces the interactions with TIP60 ([@B184]). Partial loss of TIP60 delays cerebellar degeneration in SCA1\[82Q\] transgenic mice and correlates with an increased level of RORa and RORa-dependent gene expression ([@B69]). Therefore, these results suggest a mechanism whereby increased interactions of mATXN1 with TIP60 destabilizes RORa transactivation activity, leading to reduced expression of genes important for the function and maintenance of Purkinje cells.

To further delineate the role of gene deregulation in Purkinje cells pathology, SCA1\[82Q\] mice were studied at mild, moderate and severe ataxia stages ([@B95]), and showed that downregulated genes are overrepresented at the mild stage, while the severe stage is associated with gene upregulation. Weighted gene co-expression network analysis (WGCNA) of cerebellar transcriptomes identified 2 modules of deregulated genes highly relevant for SCA1 ataxia phenotype: the so called Magenta module (MM) reflects an early and progressive signature of downregulated Purkinje cells genes, while Lt Yellow module (LtYM) concerns up- and downregulated genes associated with multicellular responses to Purkinje cells pathology ([@B95]). Ingenuity Pathway Analysis (IPA) of MM identified ATXN1 as the main upstream regulator of MM genes and highlighted the function of these genes in LTD and glutamate receptor signaling. The most connected hub genes in MM module include *Fam107b, Fam21*, *Gabbr1*, *Rgs8, Dner, Inpp5a, Trpc3, Homer3, Stac, and Grik1* and many of them code for signal transduction proteins. Importantly, SCA1^154Q/2Q^ knockin mice also show similar downregulation of Purkinje cell genes including several hub genes. Finally, promoter analysis of MM genes shows an enrichment for motifs bound by the Capicua Transcriptional Repressor (CIC), which interacts with ATXN1 (see below) ([@B95]). Together, this analysis identified a set of deregulated genes and underlying mechanisms that compromise the functions of Purkinje cells in SCA1.

A series of studies conducted in mouse models have highlighted the complex interplay between gain- and loss-of-function mechanisms at the basis of gene deregulation in SCA1. *Atxn1* knockout mice exhibit a variety of neurological deficits including motor learning, a phenotype shared with SCA1^154Q/2Q^ knockin mice ([@B132]; [@B38]). Furthermore, comparison of cerebellar transcriptomes reveals common genes deregulated in the two models ([@B38]), suggesting that loss of ATXN1 function might contribute in part to SCA1 pathogenesis. Along this line, removing the wild-type copy of ATXN1 in SCA1^154Q/2Q^ mice worsens the disease phenotype ([@B123]), while duplication of *Ataxin-1-Like* gene (*Atxn1l*), coding for a highly conserved *Atxn1* paralog with partial functional redundancy ([@B38]), suppresses behavioral phenotypes in SCA1^154Q/2Q^ mice ([@B15]), raising the possibility that ATXN1L replaces mATXN1 in native complexes. In particular, ATXN1 forms a complex with CIC in mouse cerebellum, while mATXN1 decreases the formation of the native complex ([@B123]) and alters the repressor activity of CIC *in vitro* and *in vivo* ([@B112]). Therefore, it is proposed that increased ATXN1L level by *Atxn1l* duplication in SCA1 mice displaces mATXN1 from the CIC complex, promotes its aggregation and thus restores functional ATXN1L-CIC repressor activity ([@B15]). The role of CIC in SCA1 was further explored by [@B66], who showed that increased physical activity does not improve motor phenotypes in SCA1^154Q/2Q^ knockin mice, but prolongs their survival in correlation with a decreased CIC level in brainstem ([@B66]). Furthermore, they found that deletion of one allele of CIC (CIC-L^+/--^) in SCA1^154Q/2Q^ knockin mice leads to multiple beneficial effects on motor coordination, learning and memory, Purkinje cells loss, weight loss and survival ([@B66]). Analyses of cerebellar transcriptomes and direct CIC targets identified by chromatin immunoprecipitation (ChIP) led to the conclusion that mATXN1 causes a dual effect on DNA binding properties of CIC, which binds either more tightly and hyper-repressed certain gene targets or more weakly to other targets and leads to transcriptional derepression. Together, these results indicate that mATXN1 causes concomitant gain- and loss-of-function of the same native partner. A more recent study indicates that gain-of-function of mATXN1-CIC complex might be the major factor inducing cerebellar pathology ([@B165]). Indeed, complete deletion of CIC in the cerebellum does not cause much gene deregulation, or Purkinje cells degeneration. Moreover, the expression of mATXN1 with a mutation that prevents interaction with CIC ameliorates SCA1 symptoms and reduces gene deregulations in the cerebellum of SCA1\[82Q\] mice ([@B165]). In the mouse cerebellum, ATXN1 is present in another native complex containing RBM17 and is thought to be involved in RNA splicing ([@B123]). PolyQ expansion leads to increased association with the RMB17 complex. Interestingly, loss of one *dRbm17* allele suppresses mATXN1 toxicity in the SCA1 *Drosophila* eye and overexpression of the human RBM17 worsens the phenotype, consistent with another gain-of-function mechanism. This further suggests the involvement of RNA splicing dysfunction in the pathogenesis.

Gene deregulation in SCA1 may also result from epigenetic alterations, as SCA1^154Q/2Q^ knockin mouse cerebella show a significant reduction of histone H3 acetylation, an epigenetic modification associated with gene activation ([@B41]). ATXN1 interacts with a transcriptional repressor complex formed by SMRT, NCOR2, and the histone deacetylase HDAC3 ([@B201]; [@B56]), while mATXN1 stabilizes this complex and favors transcriptional repression ([@B205]). However, deleting a single allele of HDAC3 in SCA1^154Q/2Q^ knockin mice has neither beneficial effects on motor deficits nor on Purkinje cell pathology, likely because HDAC3 is required for Purkinje cell functions as shown in conditional HDAC3 knockout mice ([@B205]). This confounding effect does not rule out HDAC3 dysfunction, but precludes pharmacological inhibition of HDAC3 in therapy of SCA1 and other polyQ SCAs ([@B205]). mATXN1 also affects the function of LANP, a protein enriched in Purkinje cells that binds the N-terminal histone tails and prevents its acetylation by HATs ([@B182]; [@B42]). mATXN1 perturbs a repressor complex formed by LANP and E4F, and relieves the transcriptional repression dependent of this complex ([@B131]; [@B42]). In addition, mATXN1 interacts and synergises with LANP to inhibit the HAT activity of CBP and to decrease transcription in N2A cells ([@B41]). Consistently, LANP depletion in these cells restores the histone acetylation level. Inactivation of *Lanp* in SCA1^154Q/2Q^ knockin mice improves the maintenance of synapses between the inferior olive (IO) neurons and Purkinje cells as measured by vGLUT2 labeling. However, this improvement is not sufficient to restore behavioral deficits, suggesting that LANP might have cell-type specific functions.

Recent studies have explored gene deregulation in extra cerebellar regions. In the medulla of SCA1^154Q/2Q^ knockin mice, deregulation occurs 10 weeks later than in the cerebellum, and concerns genes mainly involved in metabolic pathways ([@B65]). Interestingly, gene deregulation in SCA1^154Q/2Q^ mouse IO nuclei, which are highly affected in SCA1 *post-mortem* tissues, reveals the activation of the immune system including interferon stimulated genes (ISG) ([@B49]). Similar immune response activation is observed in SCA1\[82Q\] transgenic mice, despite the absence of mATXN1 expression in IO, suggesting an underlying non-cell autonomous mechanism ([@B49]). The identification of *Igfbp5* as the most robustly downregulated gene in SCA1^154Q/2Q^ and SCA7^266Q/5Q^ knockin mice revealed another non-cell autonomous mechanism ([@B211]; [@B225]). *Igfbp5* is expressed and secreted from granule neurons, and is thought to play a role in the regulation of the insulin-like growth factor (IGF) pathway by blocking the binding of IGF1 to its receptor. In SCA1 and SCA7 mouse models, the decreased level of IGFBP5 leads to the activation of IGF pathway ([@B68]). Interestingly, *Igfpb5* is also downregulated in granule neurons of SCA1\[82Q\] transgenic mice, despite the absence of mATXN1 expression in these neurons ([@B20]), leading to the abnormal activation of IGF pathway in the Purkinje cells of this model. Overall, this indicates that Purkinje cells pathology in SCA1\[82Q\] mice causes the downregulation of *Igfpb5* in granule neurons in a non-cell autonomous manner, and in turn the decreased IGFBP5 level produced by granule neurons leads to the abnormal activation of the IGF pathway in Purkinje cells. As a consequence, IGF downstream signaling leads to the activation of PI3-K/Akt ([@B68]), which can phosphorylate the Ser776 of mATXN1 and enhance its toxicity ([@B27]).

SCA2 {#S2.SS2}
----

SCA2 is caused by the expansion of a CAG triplet ranging from 33 to 500 repeats in the coding sequence of the *ATXN2* gene ([@B94]; [@B158]; [@B172]) leading to a polyQ expansion in mutant ATXN2 (mATXN2) ([@B158]). Patients suffer from ataxia, parkinsonism, dysarthria, dysmetria, action tremor, hypotonia, and slow saccades ([@B16]). Several structures like brainstem, spinal cord, thalamus, cranial nerves, and muscles are affected ([@B170]; [@B115]), but the progressive atrophy of the cerebellum with Purkinje cell death is the primarily sign of neurodegeneration ([@B59]; [@B78]; [@B4]).

ATXN2 is a cytoplasmic protein widely expressed in the brain ([@B158]). mATXN2 accumulates in the cytoplasm and nucleus and forms aggregates in SCA2 ([@B178]). ATXN2 is implicated in RNA metabolism including stability, translation, and degradation ([@B148]; [@B53]). It contains an RNA binding Lsm domain functionally relevant to pre-mRNA splicing and mRNA decay ([@B159]). ATXN2 assembles with ribosomes on the endoplasmic reticulum (ER) and interacts with the cytoplasmic poly(A)-binding protein 1 (PABP-1), a factor involved in translation initiation ([@B173]; [@B204]). It also interacts with the RNA splicing factor A2BP1/Fox1, DDX6, and TDP-43 ([@B187]; [@B148]; [@B54]). ATXN2 localizes to stress granules arresting untranslated mRNAs under cellular stress ([@B148]).

Studies in mouse models have shown the role of gene deregulation in the pathogenesis of SCA2. It is noteworthy that *Atxn2*^--/--^ KO mice develop obesity and insulin resistance and show gene deregulation in the cerebellum, despite the absence of cerebellar pathology ([@B104]; [@B114]; [@B78]; [@B76]; [@B156]). The transgenic SCA2^127Q^ mice, which express mATXN2 specifically in Purkinje cells, exhibit deregulation of genes involved in calcium signaling and changes in the firing frequency of Purkinje cells, prior to the development of a severe ataxic phenotype ([@B78]). Further temporal analysis shows that deregulation of genes involved in histone acetylation, chromatin remodeling and cell adhesion occurs as early as post-natal day 1, while genes involved in calcium signaling and glutamatergic input important for Purkinje cells are deregulated later ([@B156]). Interestingly, as for SCA1 mice, WGCNA also identified a module enriched in Purkinje cells genes involved in LTD, phosphatidylinositol, calcium and signal transduction, including the hub genes *Fam21*, *Gabbr1*, *Rgs8*, and *Lcmt*. Similar deregulation of Purkinje cells genes occurs in BAC-72Q transgenic mice, which express m*ATXN2* gene in a bacterial artificial chromosome (BAC) and show Purkinje cells pathology that precedes motor deficits ([@B43]). Deregulation also concerns genes expressed in cerebellar granule cells, indicating that mATXN2 causes dysfunction of this cell type as well ([@B43]).

mATXN2 alters gene expression in part through its dysfunctions in RNA metabolism. In BAC-Q72 mice, the level of *Rgs8* mRNA is reduced, while the level of RGS8 proteins is even more strongly decreased ([@B43]). RGS8 is a regulator of G-protein that negatively modulates GPCR signaling and its deregulation is thought to account for the deficit of the mGluR1-ITPR1 axis in SCA2 Purkinje cells ([@B139]). It was shown that ATXN2 interacts with *Rgs8* mRNA to control its translation and the protein production *in vitro*, whereas mATXN2 has decreased interaction with *Rgs8* mRNA resulting in reduced RGS8 synthesis. Interestingly, an antisense oligonucleotide (ASO) treatment lowers the level of mATXN2 and decreases the Purkinje cell pathology in SCA2 mouse models ([@B177]). The expression of 6 deregulated genes is restored to normal protein levels, while mRNA levels are restored for only 3 of them ([@B177]), suggesting that ASO primarily rescues the dysfunction of mATXN2 in RNA translation, and has partial effect on other mechanisms altering the mRNA levels ([@B43]; [@B62]).

Consistent with the demyelination reported in the brain of SCA2 patients ([@B168]), lipid profiling analysis of SCA2 patient cerebellum shows deficits for very long-chain C24 sphingomyelin, a lipid enriched in brain white matter, as well as galactosylceramide, cholesterol and other lipidic compounds typical of myelin sheets ([@B179], [@B180]). Similarly, the cerebellum and spinal cord of Atxn2-CAG100 knockin mice show a reduction of the very long-chain sphingomyelin and free ceramide species, which correlates, respectively, with the downregulation of elongase genes (*Elovl1*, *Elovl4*, and *Elovl5)* and of the *Cers1* gene involved in their synthesis ([@B179]). Therefore, the study establishes a link between the alteration of the white matter and specific gene deregulation ([@B179]).

SCA3 {#S2.SS3}
----

SCA3 is the most common dominantly inherited form of ataxia, affecting approximately 1:50,000--100,000 people ([@B52]). SCA3 neuropathology is characterized by degeneration in the brainstem, cerebellum, striatum, midbrain, thalamus, and spinal cord ([@B169]). Compared to other ataxias, the Purkinje cells are relatively well preserved, except in the cerebellar vermis. The pathology primarily affects the basis pontis and deep cerebellar nuclei resulting in enlargement of the fourth ventricule ([@B169]).

ATXN3 is an ubiquitously expressed, nucleo-cytoplasmic protein with deubiquitinase (DUB) activity ([@B155]; [@B19]) (and reviewed in [@B37]). It is proposed to play a role in PQC regulation in the cytoplasm by editing polyubiquitin chains of substrates prior to proteasome degradation or by removing polyubiquitin chains to protect some substrates from degradation ([@B23]; [@B176]; [@B206]; [@B126]). The DUB activity has additional nuclear functions, such as DNA damage repair (reviewed in [@B137]) and transcriptional regulation. The protein interacts with several transcriptional regulators including the HAT proteins CBP, P300, PCAF, and HDAC1-3 as well as PML, TBP, FOXO4, TAF130, MAML1, SC35, and NCoR ([@B24]; [@B121]; [@B60]; [@B5]). In particular, ATXN3 shows a dual effect on HDAC3 function in transcription. On the one hand, ATXN3, HDAC3, and NCoR form a deacetylation complex to repress transcription of the MMP2 gene ([@B60]). On the other hand, during viral infection, ATXN3 DUB activity protects HDAC3 from degradation to activate the interferon I pathway ([@B61]). In addition, upon heat and oxidative stress, ATXN3 activates FOXO4-mediated SOD2 expression ([@B5]). Therefore, the role of ATXN3 in gene regulation might be related to cellular response to adverse conditions, such as viral infection and stress. Accordingly, in normal husbandry condition, *Atxn3* knockout mice show only a small subset of deregulated genes ([@B160]) and appear phenotypically normal ([@B161]).

One major consequence of polyQ expansion in ATXN3 is the abnormal protein accumulation and aggregation in neuronal nuclei. Preventing nuclear localization of mutant ATXN3 (mATXN3) mitigates many disease features, while targeting mATXN3 into the nucleus worsens the phenotype of SCA3 mice ([@B12]). PolyQ expansion does not affect the DUB activity *in vitro* ([@B214]). However, mATXN3 nuclear accumulation perturbs the deacetylation activity of HDAC3-NCoR complex leading to higher expression of *MMP-2* gene ([@B60]), and compromises the FOXO4-mediated SOD2 expression during oxidative stress ([@B5]). Consistently, SOD2 is downregulated in the pons of SCA3 patients, which might increase the sensitivity of this brain region to stress.

Alterations in gene expression are reported in several cellular and mouse models of SCA3 ([@B24]; [@B121]; [@B60]; [@B35]; [@B5]; [@B195]; [@B160]; [@B198]). However, the extent and nature of gene expression changes and their pathological consequences largely vary between mouse models. Transgenic mice overexpressing *ATXN3* cDNA (Ataxin-3-Q79 mice) show motor defects and the deregulation of genes involved in synaptic plasticity correlates with LTD impairment in Purkinje cells ([@B35], [@B34]). In this model, Purkinje cells do not express mATXN3, suggesting that dysfunction occurs through deleterious effect from pre-synaptic neurons ([@B35]). In contrast to Ataxin-3-Q79 mice, models expressing physiological levels of mATXN3 do not present motor phenotype. However, since these models show polyQ aggregation and altered gene expression, they are considered as pre-symptomatic models of SCA3. The transgenic YAC84Q (MJD84.2) SCA3 mouse model expressing a yeast artificial chromosome (YAC) containing the *ATXN3* human gene with 76-77 CAG repeat expansion, shows gene deregulation in diverse brain tissues affected in SCA3 patients, such as the striatum, brainstem, cerebral cortex and cerebellum ([@B198]). Interestingly, these tissues consistently show downregulation of the CREB signaling pathway ([@B198]), in agreement with previous studies showing that mATXN3 aggregates sequester and inhibit CBP, a major transcriptional co-regulator of CREB-mediated transcription ([@B134]; [@B24]).

In a compelling study, [@B160] compared alterations of gene expression in the brainstem of different SCA3 mouse models including YAC84Q SCA3 mice, its control counterpart YAC15Q, SCA3 knockin mice with 82 CAGs, and *Atxn3* knockout mice. The mouse lines show different load of mATXN3 aggregation in the brain and the comparison provides four important information ([@B160]). Firstly, overexpression of human wild type *ATXN3* in YAC15 has little effect on gene expression and further supports its minor role in gene regulation when mice are raised in normal conditions. Secondly, the level of deregulation increases with the aggregation load in the pons of different lines, supporting a mechanism whereby mATXN3 affects the function of transcriptional regulators through sequestration in polyQ aggregates or by alteration of nuclear proteostasis (further discussed below). Thirdly, differentially expressed genes in SCA3 knockins largely differ from those in the knockout mice, implying that deregulation in SCA3 mice is not related to loss of ATXN3 function. Finally, a subset of shared genes affected in the different SCA3 mouse lines highlights alterations in the homeostasis of oligodendrocytes, where mATXN3 also forms aggregates ([@B160]). Furthermore, conditional deletion of *mAtxn3* in oligodendrocytes rescues gene deregulation in these cells, revealing cell-autonomous effects of mAtxn3 toxicity in this cell type.

Consistent with the impairment of HAT and HDAC functions, several SCA3 models present a decrease of the bulk level of histones H3 and H4 acetylation ([@B224]; [@B34]; [@B125]; [@B208]). Moreover, downregulated LTD-associated genes in the Ataxin-3-Q79 mice have hypoacetylated promoters, and cerebellar protein extracts show a reduction of HAT activity, but not HDAC activity *in vitro* ([@B34]). Treatment with the HDAC inhibitor (HDACi) sodium butyrate rescues H3 and H4 acetylation, expression of LTD-associated genes, LTD function of Purkinje cells and mice survival ([@B35], [@B33], [@B34]). Similarly, other HDACi, such as valproic acid or divalproex sodium, restore the histone acetylation level and prevent cytotoxicity in SCA3 cellular models ([@B224]; [@B125]; [@B208]) and extend the survival of a SCA3 fly model ([@B224]). At variance, valproic acid treatment of CMVMJD135 mice, which overexpress mutant *ATXN3* cDNA, only mildly attenuates the motor phenotypes ([@B58]). However, the effects of HDACi treatments need to be interpreted with caution, since they have additional effects. For instance, valproate semisodium prevents the nuclear transport of mATXN3 in cellular models, hence reducing nuclear toxicity ([@B208]), and valproic acid-treated CMVMJD135 mice show an increased expression of the ER chaperon BIP/GRP78, which may enhance the folding capacity of the ER and provide neuroprotective effects ([@B58]).

SCA6 {#S2.SS4}
----

Compared to other polyQ SCAs, SCA6 is considered a pure cerebellar ataxia with later onset and slower progression ([@B52]). SCA6 patients have a normal lifespan ([@B191]). Brain analysis shows cerebellar atrophy due to Purkinje cells degeneration ([@B219]), while other regions are less affected. The ataxia is caused by short expansions ranging from 20 to 33 CAGs in the *CACNA1A* gene, resulting in polyQ expansions in the α1A subunit of P/Q type calcium channel Cav2.1 ([@B230]). Cav2.1 is highly expressed in the cerebellum, particularly in Purkinje cells. Targeted disruption of mouse *Cacna1a* leads to gross neurological phenotype and ataxia soon after birth and to death at post-natal days 18--21 ([@B102]). Mutations in human *CACNA1A* cause episodic ataxia type 2 (EA2) and familial hemiplegic migraine type 1 (FHM1), which have distinct clinical presentation from SCA6 ([@B72]; [@B199]) and have been linked to altered calcium channel function, consistent with channelopathies. The polyQ stretch is located in the cytoplasmic C-terminus tail of the α1A subunit, which also contains residues involved in channel function and regulation ([@B22]). Therefore, many studies on SCA6 have focused on the channel function in the presence of polyQ expansion, but they generated conflictual results (review in [@B70]). In any case, the apparently normal calcium channel function observed in two knockin mouse studies weakens the channelopathy hypothesis ([@B171]; [@B210]). SCA6 mutation with 30Q causes mild clinical symptoms in patients, and no motor phenotype in knockin mice ([@B210]). The 30Q expansion might not be toxic enough to cause ataxia during the lifespan of mice, in contrast to the hyper-expanded 84Q, which produces polyQ aggregates and ataxia in another knockin mouse model ([@B210]).

Interestingly, cumulative evidence indicates that the C-terminal tail of α1A plays a physiological role as a free polypeptide in the pathogenesis. It was initially reported that α1A subunit is cleaved to release a stable C-terminal fragment that translocates to the nuclei of Purkinje cells ([@B109]; [@B108]). The polyQ expansion does not influence the cleavage and nuclear localization, but confers cytotoxic properties to the fragment. Of greater interest, [@B50] found that the *CACNA1A* transcript is bicistronic and harbors a functional internal ribosomal entry site (IRES) and encodes two proteins, the α1A subunit and a transcription factor named α1ACT, which corresponds to the C-terminal tail. Several evidence shows that α1ACT localizes to the nucleus and activates the expression of genes involved in neurite outgrowth and Purkinje cells development such as *TAF1*, *BTG1, PMCA2*, and *GRN*. Overexpression of wild type α1ACT~wt~ partially rescues the severe phenotype of *Cacna1a* knockout mice. α1ACT harboring the SCA6 mutation (α1ACT~sca6~) also translocates to the nucleus but loses the capacity to activate the expression of these Purkinje cells genes and to rescue *Cacna1a* knockout mice ([@B50]). Importantly, the overexpression of α1ACT~sca6~, but not the wild type form causes a mild ataxia and cerebellar cortical atrophy in transgenic PC-α1ACT~sca6~ mice ([@B50]). Therefore, rather than a channelopathy, the pathogenesis of SCA6 appears to be related to gene deregulation and to share the pathomechanisms of other polyQ SCAs.

It is noteworthy that SCA6 patient-derived induced pluripotent stem cells (iPSCs) provides an excellent model of the pathogenesis ([@B96]). SCA6 iPSCs differentiate into Purkinje cells with the same efficiency as control iPSCs. Similar to observations in patients ([@B97]), the α1A subunit abnormally accumulates in SCA6 Purkinje cells. At the opposite, the nuclear α1ACT is found at a much lower level in SCA6 Purkinje cells compared to control, correlating with the decreased expression of *TAF1* and *BTG1* mRNA and proteins ([@B96]). Compared to controls, the *in vitro* maintenance of SCA6 Purkinje cells depends of thyroid hormone T3 in the medium. However, the relationship between T3-dependent maintenance of Purkinje cells and the decreased expression of Purkinje cell genes such as *TAF1* and *BTG1* remains to be investigated.

SCA7 {#S2.SS5}
----

SCA7 is due to CAG expansions ranging from 34 to more than 400 triplets in the gene coding for ATXN7 ([@B44]; [@B16]). The main symptoms of SCA7 are gait and stance ataxia which are often accompanied by dysphagia. Additional symptoms include spastic ataxia, intentional tremors, slow eye movement, ophthalmoplegia, as well as pyramidal signs. These symptoms are caused by the loss of Purkinje cells and additional neuronal loss in the granular cell layer, the dentate nuclei, the IO nuclei as well as a mild neuronal loss in the basis pontis, and an atrophy of the spinocerebellar tracts ([@B141]; [@B167]). SCA7 is the only polyQ SCA to cause cone and rod photoreceptor dystrophy responsible for a decrease of visual acuity ([@B141]).

ATXN7 is a ubiquitously expressed nucleo-cytoplasmic protein, which has an important nuclear function as a component of the Spt-Ada-Gcn5 Acetyltransferase complex (SAGA) ([@B175]; [@B85]; [@B118]; [@B154]). SAGA harbors 2 enzymatic modules: a HAT module containing the acetyltransferases KAT2A/GCN5 or KAT2B/PCAF, involved in the acetylation of lysine 9 of histone H3 (H3K9) ([@B14]; [@B122]), and a DUB module containing the deubiquitinase USP22, which removes monoubiquitin from lysine 120 of histone H2B ([@B14]). ATXN7 is part of the DUB module, together with USP22, ENY2, and ATXN7L3 (a paralog of ATXN7) and anchors DUB in the core of SAGA. It was shown that SAGA is a general coactivator of RNAPII-driven transcription, which acetylates H3K9 on gene promoters and deubiquitinates H2B in the transcribed region of expressed genes ([@B14]). Besides a general coactivator role, SAGA is likely to have more specific functions in gene regulation ([@B122]). Interestingly, inactivation of the zebrafish *atxn7* gene causes incomplete differentiation of Purkinje cells and photoreceptors, two major neuronal cell types affected in the disease ([@B222]; [@B21]). Recent studies in yeast indicate that *sgf73*, the ortholog of *ATXN7*, is involved in yeast longevity (calculated as the number of division a cell can achieve before going through senescence) by controlling the expression of ribosomal protein coding genes and by interacting with sirtuin2 ([@B135]; [@B130]).

Different studies were conducted *in vitro* and in cellular and various mouse models to determine the impact of the polyQ expansion of ATXN7 on SAGA enzymatic activities and gene expression. Notably, transgenic and knockin mouse models recapitulate the retina and cerebellar pathologies observed in SCA7 patients ([@B229], [@B228]; [@B110]; [@B225]; [@B32]; and reviewed in [@B103]) and important gene deregulations are observed in these affected tissues ([@B110]; [@B1]; [@B83]; [@B68]; [@B32]). Several initial reports showed that mutant ATXN7 (mATXN7) is incorporated into SAGA ([@B152]; [@B83], [@B84]). An *in vitro* reconstituted DUB module containing mATXN7 shows normal deubiquitination activity on core histone ([@B113]), while other *in vitro* experiments lead to less consistent conclusion about the deleterious effects of mATXN7 on the KAT2A/GCN5-mediated HAT activity of SAGA ([@B138]; [@B152]; [@B83]; [@B18]). In SCA7 mouse models, one of the major consequence of polyQ expansion is the progressive accumulation and aggregation of mATXN7 in the nuclei of neurons, including photoreceptors and Purkinje cells ([@B229], [@B228]; [@B110]; [@B225]). mATXN7 is also a substrate of caspase7 and a caspase7-released fragment containing the polyQ expansion is found in patients' cells and in the cerebellum of SCA7 mouse model ([@B67]; [@B226]). Preventing proteolysis of mATXN7 by mutation in the caspase7 cleavage site reduces the aggregation and the phenotypes of SCA7 transgenic mice ([@B75]).

High levels of mATXN7 in the nucleus might alter SAGA function in several manners. In particular, KAT2A/GCN5, ATXN7L3, and USP22 are sequestered in mATXN7 aggregates in cultured cells ([@B116]; [@B113]; [@B218]). Analysis of protein extracts from SCA7 knockin mouse cerebellum and astrocyte cells overexpressing mATXN7 shows that the bulk level of H2Bub is increased, suggesting that mATXN7 might cause a general dysfunction of DUB-SAGA ([@B113]; [@B145]). However, transcriptome comparison of astrocyte cells expressing wild type or mutant ATXN7 identifies very few differentially expressed genes ([@B136]). Among which, the reduced expression of *RELN* consistently correlates with the reduced occupancy by mATXN7 and the increased monoubiquitinated H2B on *RELN* promoter ([@B136]). RELN is involved in the development and maintenance of Purkinje cells ([@B142]) and the effect of its deregulation in SCA7 pathology remains to be determined. The small subset of genes deregulated in mATXN7-expressing astrocytes is at odd with the apparent general dysfunction of SAGA-DUB caused by mATXN7.

The involvement of KAT2A/GCN5 in the SCA7 pathology was directly assessed in SCA7^100Q/100Q^ knockin mice. The deletion of one *Kat2a/Gcn5* allele accelerates the cerebellar and retinal pathology, but does not worsen gene deregulation ([@B29]), suggesting that a non-transcriptional function of KAT2A/GCN5 might contribute to SCA7 pathogenesis. Consistently, conditional deletion of *Kat2a/Gcn5* in Purkinje cells of wild type mice does not lead to severe ataxia ([@B29]). It is possible that other redundant HATs, like KAT2B/PCAF which is also present in SAGA ([@B144]; [@B190]), can compensate for the lack of KAT2A/GCN5. Therefore, the extent to which SAGA-HAT dysfunction contributes to Purkinje cells degeneration in SCA7 remains to be explored. As in SCA1, Purkinje cells degeneration may involve the dysfunction of RORa. Indeed, RORa transactivation activity on gene reporter system is repressed by mATXN7 in cultured cells ([@B193]), warranting further investigation of RORa dysfunction in SCA7 mouse cerebellum.

As in SCA3 mice, the SCA7 transgenic ataxin-7-Q52 mice present a deregulation of genes involved in the oligodendrocyte myelinogenesis pathway including the transcription factor *Olig1*, suggesting that SCA7 mutation also affects glial cells ([@B32]). Consistently, transgenic PrP-SCA7-92Q and Gfa2-SCA7 mouse models show clear degeneration of the Bergmann glia in the cerebellum ([@B40]). Interestingly, Purkinje cells also degenerate in these models, despite the absence of mATXN7 expression in these neurons, indicating a non-cell autonomous mechanism induced by Bergmann glia dysfunction ([@B40]). In these mice, Bergmann glia express a low level of the glutamate transporter GLAST, reducing glutamate uptake at the Purkinje cells synaptic region and leading to glutamate excitoxicity ([@B6]; [@B40]). Study of the SCA7 transgenic mouse fxSCA7 92Q, which widely overexpresses mATXN7 in the brain, further highlights the deregulation of Purkinje cell-specific genes involved in calcium and phosphatidylinositol signaling ([@B192]). Promoter analysis of downregulated genes identifies an enrichment for DNA motifs bound by PGC-1α and HIF-1α transcription factors, which functions are positively regulated by the deacetylatase SIRT1 ([@B162]; [@B101]). Interestingly, SCA7 mice show an increased acetylation of PGC-1α and a decreased level of NAD^+^, a cofactor of SIRT1, suggesting an alteration of SIRT1 activity ([@B192]). Indeed, overexpression of SIRT1 in SCA7 mice restores the expression of calcium related genes, reduces the Purkinje cells pathology and enhance mice survival ([@B192]). Similarly, replenishment of NAD^+^ through supplemented diet improves the phenotype of SCA7 mice and restores the calcium homeostasis in neuronal progenitor cells derived from SCA7 iPSCs.

The mechanisms underlying SCA7 retinopathy have been the subject of many studies, because photoreceptors are the first to degenerate and as they represent 70% of neuronal cells in the retina, their function is easily assessed by electroretinograph activity. Electroretinograph dysfunction in SCA7 transgenic and knockin mouse models closely correlates with the progressive reduction of photoreceptor-specific genes expression essential for phototransduction and outer segment formation ([@B229]; [@B110]; [@B225]; [@B1]; [@B83]). Consistently, SCA7 mouse photoreceptors progressively lose their outer segments ([@B223]), a structure entirely filled with discs of folded double membranes where phototransduction takes place. Since a proportion of outer segments is normally lost every day due to degradation, sustained expression of photoreceptor genes is essential to ensure the renewal and integrity of outer segments. The renewal process necessitates a high biosynthetic regime and a specific gene expression programs ([@B215]). Notably, the transcription factors CRX, NRL, and NR2E3 play major roles in the development, differentiation and maintenance of photoreceptors ([@B194]). Many CRX- and NRL-regulated genes are downregulated in SCA7 retina ([@B110]; [@B1]). It was shown that CRX requires interaction with ATXN7 and SAGA to be fully functional on photoreceptor gene promoters ([@B152]) and mATXN7 suppresses CRX transactivation activity in SCA7 transgenic mouse retina ([@B110]; [@B28]). Consistently, promoters of photoreceptor-specific genes downregulated in SCA7 retina show hypoacetylation of histone H3 ([@B152]), due to a dysfunction of the HAT activity of SAGA. Accordingly, a decreased level of RNAPII was also reported on the promoter of these genes ([@B83]). In addition to a reduced CRX transactivation activity, the expression level of CRX as well as NRL is reduced in SCA7 retina, enhancing the downregulation of their target genes ([@B1]; [@B83]). Another study shows that the proteotoxicity in SCA7 retina leads to hyperphosphorylation and activation of c-JUN, a transcription factor involved in the cellular stress response ([@B140]). Interestingly, in SCA7 mice expressing a phosphorylation-resistant c-JUN, the expression level of *Nrl* is partially restored and correlates with a delay of SCA7 retinopathy. Additional analysis shows that c-JUN binds *NRL* promoter and inhibits its expression on reporter gene assay in HEK293 cells ([@B140]).

The mouse photoreceptor has an atypical chromatin organization with a single cluster of heterochromatin surrounded by euchromatin along the nuclear membrane ([@B105]). Photoreceptor nuclei of SCA7 transgenic and knockin mouse models have an aberrant chromatin profile with enlarged nuclei and significant chromatin decompaction ([@B83]). Chromatin decondensation might result from a decreased expression of histone H1C, which is involved in the proper compaction of photoreceptor chromatin during rod development ([@B157]). It was suggested that chromatin decompaction and nuclear enlargement lead to dilution of transcription factors and primarily affect the expression of highly expressed photoreceptor specific genes ([@B86]). Therefore, different mechanisms related to SAGA dysfunction and proteotoxicity account for the loss of gene expression and maintenance of photoreceptors in SCA7 retinopathy. It is noteworthy that TFIIF and TFIID components (but not TBP) and CBP are sequestered in mATXN7 aggregates ([@B228]) and that ATXN7 interacts with HDAC3 in SCA7 mice ([@B51]). However, the role of these factors and co-regulators of transcription in SCA7 gene deregulation has not been addressed so far.

A study showed that mouse ATXN7 autoregulates its expression level through a mechanism that involves the microRNA miR-124 ([@B196]). In the presence of mATXN7, SAGA dysfunction leads to lower expression of miR-124, which accelerates toxicity by over-production of mATXN7. In addition, miR-124 regulates the level of *lnc-SCA7* RNA, which itself positively influences the level of *Atxn7* mRNA by an unknown mechanism. As a consequence, the high level of *lnc-SCA7* RNA also contributes to sustain the high level of *mAtxn7* mRNA. It is proposed that these RNA crosstalks could explain the high level of mATXN7 expression in the retina and the cerebellum, accounting for the vulnerability of these tissues to the disease.

SCA17 {#S2.SS6}
-----

SCA17 presents a broad spectrum of phenotypes including ataxia, dementia, chorea, and psychiatric symptoms ([@B200]). SCA17 neuropathology is characterized by atrophy of the cerebellum with major loss of Purkinje cells. Additional neurodegeneration is observed in cortical structures, caudate and putamen as well as hippocampus, parahippocampal gyrus, substantia nigra, brainstem reticular formation, and inferior olivary nucleus ([@B200]).

SCA17 is caused by the expansion of more than 40 CAGs in *TBP* gene, which encodes the TATA-box-binding protein, a component of the general transcription factor TFIID. TBP has a critical function in gene transcription and knockout mice die at early embryonic stage ([@B129]). TBP binds to basic promoter DNA motifs through its C-terminal domain, while the N-terminal extension that contains the polyQ domain modulates DNA binding and protein interactions ([@B8]). TBP is involved in the transcription driven by polymerases RNAPI, RNAPII, and RNAPIII ([@B80]) and more than 11 000 TBP binding sites in promoters of transcribed genes have been found in HEK293 cells ([@B80]). In particular, TBP and 13 TBP-associated proteins (TAFs) form the TFIID complex, which binds to different DNA motifs located within the gene promoter region including the TATA box. This event is followed by subsequent binding of the other general transcription factors TFIIA, TFIIB, and TFIIE ([@B17]) to form the transcriptional pre-initiation complex (PIC) to recruit RNAPII for transcription. For RNAPI and RNAPIII-driven transcription, TBP is associated with the multiprotein complexes SLI and TFIIIB, respectively ([@B117]; [@B36]; [@B93]).

As for the other polyQ SCAs, mutant TBP (mTBP) forms nuclear aggregates in different brain regions of SCA17 patients and SCA17 mouse models ([@B200]). mTBP proteolytic cleavage generates an N-terminal fragment containing the polyQ expansion, which is involved in the formation of polyQ aggregates in SCA17 mice ([@B64]). PolyQ expansion in mTBP impacts on gene expression through different mechanisms including aberrant protein--protein interactions, protein sequestration within aggregates and decreased binding to target DNA sequences ([@B63], [@B64]). For instance, transgenic TBP-105Q-T mice show gene deregulation, a severe motor phenotype and premature death ([@B63], [@B64]). TFIIB is sequestered in mTBP aggregates in this model. Interestingly, the expression of *Hspb1* gene (also named *Hsp27*), which encodes a chaperone involved in axonal and neuritic integrity and neuroprotective effects ([@B186]), is significantly decreased. Downregulation of *Hspb1* correlates with the reduced occupancy of mTBP and TFIIB on its promoter. Overexpression of TFIIB or HSPB1 has protective effect and prevents neurite disruption in differentiated PC12 cell models of SCA17 ([@B63]).

Increased production of reactive oxygen species and induction of ER stress are observed in SCA17 lymphoblastoid cell lines ([@B120]). The unfolded protein response (UPR) is a protective pathway and relies in part on the activation of XBP1, which forms complexes with different transcription factors including TBP, ATF6, and the NFY complex ([@B164]; [@B87]). There are evidences that the UPR is compromised in SCA17. For example, NFYA, a regulatory unit of NFY complex, is sequestered in mTBP aggregates in SCA17 transgenic mice and cultured cells, and is thus decreased on target promoters, such as *HSPA5*, leading to reduced ER stress response ([@B91]; [@B119]). Furthermore, the XBP1-regulated *Manf* gene, coding for a neuroprotective factor ([@B79]), is strongly downregulated in the cerebellum of SCA17 TBP-105Q knockin mice ([@B220]). In cultured cells expressing mTBP, XBP1 shows a decreased binding to the *MANF* promoter. Interestingly, SCA17 TBP-105Q knockin mice that overexpress *MANF* in the brain show a significant improvement of motor phenotypes and a decrease of Purkinje cell degenerative signs ([@B220]). MANF protective effect on Purkinje cells appears to involve the protein kinase C signaling pathway. Therefore, mTBP appears to alter the transactivation activity of XBP1 and NFY, causing downregulation of their target genes involved in the ER stress response and signaling pathways. Interestingly, a FDA approved drug called piperine is found to induce MANF activity and to improve motor performance of SCA17 knockin mice ([@B74]). Similarly, treatment with Shaoyao Gancao Tang reduces mTBP aggregation, increases expression of *NFYA* and *HSPA5* as well as *PGC-1α* and *NRF2*, and improves motor phenotypes of SCA17 transgenic mice ([@B26]).

Alteration of neurite outgrowth in different cellular and mouse models of SCA17 correlates with decreased expression of the *Trka* gene encoding the receptor of the nerve growth factor ([@B25]; [@B185]). Analysis of *Trka* promoter sequence identifies a binding site for the Specificity Protein 1 (SP1) ([@B185]), which is known to interact with TBP ([@B55]). In cultured cells overexpressing mTBP, SP1 is not sequestered in aggregates, but shows a decreased transactivation activity in reporter gene assay ([@B185]). In the TBP-105Q knockin mice, abnormal activity of SP1 causes a decreased level of INPP5A, a protein strongly enriched in Purkinje cells and involved in the degradation of IP3 ([@B127]). Importantly, downregulation of *Inpp5a* in TBP-105Q knockin mice increases the IP3 levels and leads to Purkinje cells degeneration, while overexpression of *Inpp5a* through AAV viral vector decreases IP3 level and reduces Purkinje cells loss.

[@B221] used mouse genetic approach to study the effect of mTBP expression in neuronal and glial cells on the phenotype. While expression of mTBP in neurons and astrocytes alone has mild effect, the expression in both cell types exacerbates mouse phenotypes and Purkinje cell degeneration. Furthermore, using co-culture of primary astrocytes and neurons, the authors showed that mTBP-expressing astrocytes activate inflammatory signaling pathways and cause neuronal degeneration, which is prevented by blocking the nuclear signal kB (NF-kB) pathway. This study nicely illustrates that the synergistic toxicity of mTBP in neuronal and glial cells is critical for SCA17 pathogenesis.

Patients with long CAG repeats present a severe phenotype with muscle weakness ([@B128]). SCA17 floxed TBP-105Q knockin mice where mTBP is only expressed in muscle shows muscle degeneration with fragmented muscle morphology and centrally positioned nuclei ([@B92]). Gene expression analysis reveals a strong deregulation of muscle specific genes such as *Calc-l*, *Myo-bpc2*, *Ckm*, or *Trim72* and decreased level of MYOD, a key transcription factor required for a proper differentiation and maintenance of myoblasts ([@B46]) and known interactor of TBP ([@B82]). Analysis of the muscle cell line C2C12 expressing mTBP indicates that MYOD has decreased occupancy on promoters of target muscle genes such as *Mhc4* and *Mck*. Importantly, overexpression of MYOD alleviates muscle degeneration in TBP-105Q knockin mice, further confirming its central role in SCA17 muscle pathology ([@B92]).

Perspectives and Opportunities {#S3}
==============================

Converging Disease Pathways and Shared Pathomechanisms {#S3.SS1}
------------------------------------------------------

Despite shared genetic, clinical, and neuropathological features of polyQ SCAs, we still need a deeper understanding of the points of intersection and divergence of the pathophysiology of these diseases. A number of reviews have already compared the major features of cerebellar degeneration found in animal models with ataxic symptoms and pointed out commonly altered signaling pathways, especially affecting the physiology of Purkinje cells ([@B139]; [@B89]). The system biology approaches have examined human cerebellar gene expression data and identified modules of cerebellar co-expressed genes correlating with ataxia ([@B10]). Recently, new knockin mouse models of polyQ SCAs, which recapitulate the expression of the disease mutation in accurate spatio-temporal manner in tissues, appeared to be excellent tools for more accurate exploration of the pathophysiology of polyQ SCAs. In the future, the comparison of differentially expressed genes in each polyQ SCA, for a particular tissue or cell type at equivalent disease stage, should provide opportunities to uncover the shared pathogenic signatures, paving a way to novel therapeutic strategies that could prove beneficial for multiple SCAs.

Several converging disease pathways in polyQ SCAs have already been identified. Comparison of gene expression data revealed common deregulation of the IGF signaling pathway in SCA1 and SCA7 knockin mouse models ([@B68]). In addition, WGCNA analysis of differentially expressed genes in SCA1 and SCA2 mice identified similar modules and hubs of Purkinje cell-enriched genes and highlighted common altered pathways such as LTD, phosphatidylinositol, calcium, and cell signaling ([@B124]; [@B183]; [@B95]; [@B156]). Many of the reported Purkinje cell-enriched genes were also deregulated in SCA3, SCA7, and SCA17 ([Figure 1](#F1){ref-type="fig"}; [@B35], [@B33], [@B34]; [@B192]; [@B127]). Direct comparison of polyQ SCA gene deregulation is thus warranted to highlight essential points of intersection in the pathogenesis of polyQ SCAs. For instance, the relevance of *Inpp5a* downegulation in Purkinje cells degeneration has already been tested in SCA17 ([@B127]) and is likely to be demonstrated in other polyQ SCAs as well. Other converging disease pathways are implicated in the activation of immune response genes including interferon response and chronic neuroinflammation, and are prominent in SCA1, SCA3, SCA6 SCA7, and SCA17 as well as HD ([@B140]; [@B31]; [@B3]; [@B221]; [@B49]; [@B153]; [@B127]; [@B145]). Cross analysis of polyQ SCAs will help to understand how and when these injury responses are activated and their exact roles in the pathogenesis. One emerging theme that appears common in mouse models of SCA2, SCA3, SCA7, and other polyQ disorders is the deregulation of genes involved in myelination of oligodendrocytes and maintenance of their functions ([@B32]; [@B90]; [@B160]; [@B179], [@B180]). Since patients show clear atrophy of the white matter in different brain regions, the mechanisms underlying the pathology of glial cells deserve further investigation. There is thus a need for a higher, namely cell-type specific resolution of gene expression studies of polyQ SCA models. Single-cell transcriptome approaches are becoming more standardized ([@B111]; [@B174]) and open new opportunities. Other approaches allow the analysis of cell-type specific gene deregulations without the need for transgenic animals ([@B217]), which can be extremely powerful. Challenging the spatial organization of transcriptomes is currently the next step for the precise understanding of how cerebellar circuits are affected. Recent technological break-through allows to follow gene expression changes in a high spatial resolution in tissues ([@B57]; [@B163]).

![Schematic of Purkinje cell enriched gene deregulations in polyQ SCAs affecting glutamatergic synapse. Deregulations of gene expression in Purkinje cells result in alterations of the protein level of ion channels, glutamate transporters, and receptors together with downstream effectors. Production of secondary messengers and calcium homeostasis are impaired, which leads to alteration of long-term depression and pacemaker activities.](fnins-14-00571-g001){#F1}

Further comparative studies on factors involved in transcription might help to shed light into shared pathomechanisms of gene deregulation induced by polyQ expansion in disease proteins ([Figure 2](#F2){ref-type="fig"}). For example, SCA1, SCA2, and SCA7 gene expression data already identified the deregulation of common RORa-target genes in mouse models ([@B184]; [@B156]). RORa is an important transcriptional activator of genes involved in calcium homeostasis and the maintenance of Purkinje cells ([@B77]; [@B184]). It was shown that mATXN1 destabilizes RORa transactivation activity through aberrant interaction with TIP60 ([@B184]). A possible interconnection between the mechanisms whereby mATXN1, mATXN2, and mATXN7 cause RORa dysfunction represents an interesting hypothesis. Along this same line, cumulative evidences indicate that like TFIID, the SAGA complex can deliver TBP to gene promoters ([@B11]). SAGA and TFIID share five TAFs and both complexes are required for global gene expression in yeast ([@B7]; [@B209]). Recent structural examination of SAGA associated with TBP provides additional information about the deposition of TBP on gene promoters ([@B154]). Therefore, comparison of cerebellar or cell-type specific transcriptomes of SCA7 and SCA17 knockin mouse models is likely to unveil common mechanisms of gene deregulation and provide further insight into the natural function of SAGA and TFIID in mammalian cells. An additional line of converging mechanism concerns the alteration of nuclear proteotasis. A consistent observation in mouse models of polyQ disorders is an early and progressive accumulation of the disease protein in the nucleus. This suggests that mechanisms of PQC in the nucleus become rapidly overwhelmed by the increased abundance of misfolded proteins. Compared to other cellular compartments, the nucleus has a relatively distinct ubiquitin-proteasome system ([@B100]) and lacks macroautophagy, a mechanism involved in aggregate clearance in the cytoplasm. Several players of PQC such as chaperones and proteasomes are sequestered in polyQ aggregates ([Figure 2](#F2){ref-type="fig"}) and might be depleted for their interactions with other nuclear proteins. As proposed earlier ([@B188]), perturbation of nuclear proteostasis network by chronic proteotoxic stress may impact on diverse nuclear functions including gene expression and epigenetics and contribute to protein conformation diseases. Since causative SCA proteins associate with various interactors ([Table 1](#T1){ref-type="table"}), accumulation of mutant monomeric, oligomeric, or truncated polyQ proteins in the nucleus is likely to alter (sub)complex stoichiometry or cause aberrant or promote novel deleterious interactions.

![Wild type and pathological functions of polyQ SCA proteins in gene expression. Wild type SCA proteins participate to various regulatory steps of gene expression, such as binding to DNA sequences (α1ACT and TBP), modulating repression or activation activities of transcription factors (TF) (ATXN1, ATXN3, ATXN7, and TBP), modifying epigenetic marks on promoters (ATXN7/SAGA and ATXN3/HDAC3/SMRT/NCOR complexes), assembling pre-initiation complex (PIC) (TBP/TFIID) that includes general transcription factors (GTFs), deubiquitinating substrates (ATXN3 and ATXN7/SAGA) and participating to RNA metabolism (ATXN1 and ATXN2). Due to abnormal interactions with their native partners, mutant SCA proteins alter (1) the activation or repressor activities of TFs, (2) the epigenetic marks of histones involved in chromatin opening, (3) the formation of PIC recruiting RNAPII on gene promoters, and (4) the transcription elongation mediated by phosphorylated RNAPII (p-RNAPII) and by histone modification on the gene body. Mutant SCA proteins also alter (5) the post-translation modification (PTM) of nuclear proteins, (6) RNA splicing and (7) other RNA processing such as translation. In addition, (8) mutant SCA proteins form soluble oligomers and insoluble aggregates that sequester native protein partners and proteins involved in nuclear proteostasis, accounting for perturbation of gene expression. ub, ubiquitin; ac, acetyl; RBP, ribosome binding proteins.](fnins-14-00571-g002){#F2}

Broader Aspects of Gene Deregulation on the Cellular Pathology {#S3.SS2}
--------------------------------------------------------------

Precise regulation of gene expression is essential for neuronal development, function, and maintenance. Transcription of protein coding genes requires the coordinated action between specific DNA elements, transcription factors and epigenetic modulators. Subsequent steps of transcriptional elongation, RNA processing, export, translation and degradation, further shape what cells get as net products. Another orchestrating mechanism controlling the gene expression is a crosstalk between main transcriptional apparatus and non-coding RNAs (ncRNA) (e.g., microRNAs, long ncRNA, enhancer RNA, etc.). Wild type SCA proteins are involved in multi-level gene expression regulation ([Figure 2](#F2){ref-type="fig"}), which are the areas to identify the pathomechanisms underlying gene deregulation in polyQ SCAs. However, except for microRNAs (see review [@B48]), many aspects of gene deregulation remain poorly explored in the context of polyQ SCAs and warrant further investigation.

Few studies have investigated the epigenetic aspects of gene deregulation of polyQ SCAs ([Table 2](#T2){ref-type="table"}). Histone modifications such as acetylation or ubiquitination, have often been analyzed at the bulk level or on selected promoters, while genome-wide analysis using ChIP followed by high-throughput sequencing (ChIP-seq) is likely to provide a more complete view on the role of epigenetic marks in the disease. For instance, the studies of HD mouse models have shown that histone deacetylation and transcriptional deregulation correlated for only a subset of deregulated genes, which, however, have high significance for the pathology ([@B203]). In another case, hypoacetylated promoters of neuronal identity genes correlated with increased susceptibility to transcriptional deregulation and to association with additional epigenetic impairments of trimethylation of lysine 4 of histone H3, a mark of active transcription ([@B73]).

Several studies have established that superenhancers, which are large clusters of enhancers characterized by hyperacetylation of lysine 27 of histone H3 (H3K27ac) are involved in the expression of cell identity genes ([@B88]; [@B212]). A recent study identified many neuronal genes expressed in the mouse striatum associated with H3K27 hyperacetylated regions characteristic of superenhancers ([@B2]). In HD mice, striatal genes, which were associated with these putative superenhancer regions, bore H3K27 hypoacetylation and were preferentially downregulated, suggesting that affected neurons in HD progressively lose the expression of neuronal identity genes ([@B2]). One HAT responsible for H3K27ac is CBP, which is sequestered in polyQ aggregates in HD as well as in polyQ SCAs ([@B134]; [@B149]; [@B228]; [@B99]). This could suggest that neurons vulnerable in polyQ SCAs might also preferentially lose the expression of neuronal identity genes. Purkinje cells in most polyQ SCAs indeed showed decreased expression of cell-type specific genes ([Figure 1](#F1){ref-type="fig"}). Along this line, we have previously proposed that photoreceptors in SCA7 mice progressively lose their neuronal identity based on several observations ([@B146]). Notably, results from several studies indicated that SCA7 photoreceptor dysfunction correlates with the early and progressive reduced expression of most photoreceptor-specific genes important for phototransduction and outer segment formation ([@B229]; [@B110]; [@B225]; [@B28]; [@B152]; [@B1]; [@B83]; [@B223]). Moreover, inhibition of zebrafish *atxn7* leads to incomplete differentiation of photoreceptors ([@B222]; [@B21]). These observations in SCA vulnerable cells thus call for additional genome-wide analyses of epigenetic marks associated with the expression of neuronal cell identity genes.

Finally, impaired epigenetic programs may link the pathogenesis of polyQ SCAs and aging. Aging is recognized as a significant risk factor for polyQ SCAs and other neurodegenerative disorders and the link between aging, epigenetic and chromatin alterations is now established (reviewed in [@B181]). Aged mice show alterations of histone acetylation/methylation levels, leading to an increase in repressive marks and a decrease in activating marks. The question whether age-dependent epigenetic alterations superimpose to other disease-related modifications and contribute to neuronal demise is now being addressed in HD and other neurodegenerative disorders ([@B9]).

Global gene expression studies in polyQ SCA mouse models have generally pointed out the deregulation of a relatively small number of genes in a given tissue or cell type. This is consistent with our current understanding of pathomechanisms whereby polyQ SCA proteins affect a discreet set of transcription factors or co-regulators leading to deregulation of a specific subset of genes, which appear crucial for the function and survival of targeted neurons. However, one should keep in mind that classic molecular techniques only measure the steady-state level of RNA molecules. The recently uncovered phenomenon of transcription buffering (reviewed in [@B81]; [@B197]), allows a certain level of cross-talk between cytoplasm and nucleus to adjust and maintain constant mRNAs level in yeast. In particular, yeast studies showed that inactivation of subunits of TFIID ([@B209]) or SAGA ([@B7]) lead to a global decrease of transcription, but was followed by transcription buffering. Transcription buffering may thus mask more global alterations of gene transcription in SCA7, SCA17, and possibly in other polyQ SCAs. Therefore, re-evaluation of transcription dysregulation by the analysis of nascent RNA ([@B133]) or of genome-wide patterns of phosphorylated RNAPII ([@B81]) may provide new insight into the pathomechanisms underlying polyQ SCAs.

Restoring Proper Gene Expression {#S3.SS3}
--------------------------------

A number of strategies have been developed to restore proper gene expression in preclinical models of polyQ diseases and led to improve phenotypes ([@B216]). As previously discussed, alterations of histone acetylation in SCA3 models led to several attempts to correct gene deregulation and disease phenotype by using different HDACi. However, it remains unclear whether the beneficial effects of treatments are related to the correction of gene expression or to other neuroprotective effects of the drugs ([@B33]; [@B58]; [@B208]). Similarly, treatment of astrocytes expressing mATXN7 with the HDACi led to partial restoration of *RELN* gene expression by promoting the aggregation of mATXN7 into large aggregates and preventing its deleterious effect on *RELN* promoter ([@B136]). It is also noteworthy that HDAC3 haploinsufficiency does not rescue the phenotype of SCA1 mice ([@B205]), possibly due to the important role of HDAC3 in Purkinje cells function and survival ([@B205]). Therefore, the use of HDACi in treatment of polyQ SCAs is currently hampered by our limited knowledge of HDAC roles on neuronal physiology and the pleiotropic effects of the drugs ([@B47]). Since downregulation of Purkinje cells genes in SCA7 mice was associated to the reduced function of SIRT1, an approach was developed to restore SIRT1 function using NAD+ repletion to improve the phenotype ([@B192]). SIRT1 is also a target for HD and other neurodegenerative disorders and different strategies are being developed to potentiate its function ([@B207]; [@B213]). Interestingly, the development of RNA silencing strategies to reduce mutant protein expression in mouse models has led to concomitant improvement to gene expression and disease phenotypes in SCA1, SCA2, and SCA7 ([@B177]; [@B65]; [@B147]), further highlighting the proxy of gene deregulation with the etiology of polyQ SCAs.
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